| Nesiritide | restenosis after PCI, in all type of patients | vs placebo | NS | by 32% | NS | by 49% | by 79% | by 36% | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.23 [0.43 3.48] | p=1.00 | 0 | 876 | 3 | PREVENT, INHIBIT, START, | | MACE | 0.68 [0.50 0.93] | p=0.04 | 0 | 876 | 3 | PREVENT, INHIBIT, START, | | myocardial infarction (fatal and non fatal) | 0.84 [0.34 2.05] | p=1.00 | 0 | 876 | 3 | PREVENT, INHIBIT, START, | | target lesion revascularisation | 0.51 [0.32 0.80] | p=0.04 | 0 | 544 | 2 | PREVENT, START, | | angiographic restenosis | 0.21 [0.06 0.69] | p=0.04 | 0 | 96 | 1 | PREVENT, | | target-vessel revascularization | 0.64 [0.46 0.88] | p=0.04 | 0 | 876 | 3 | PREVENT, INHIBIT, START, | | Late lumen loss | no data | | Change in MLD | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PREVENT, 2000 | intracoronary radiotherapy with the beta-emitting (32)P, 16, 20, or 24 Gy to a depth of 1 mm in the artery wall | sham procedure | patients with de novo (70%) or restenotic (30%) lesions who were treated by stenting (61%) or balloon angioplasty (39%) | | INHIBIT, 2002 | intracoronary beta radiation with a phosphorus-32 source | placebo | patients with in-stent restenosis and successful coronary intervention | | START, 2000 | intracoronary radiation with 90Sr/90Y source | placebo | patients with in-stent restenosis |
|
